Gerger, Armin <br/><br/>
Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Sep 2011 
 - 5783-92 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-11-1115  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Alleles<br/>Angiogenesis Inhibitors--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bevacizumab<br/>Capecitabine<br/>Chemokines--genetics<br/>Colorectal Neoplasms--blood supply<br/>Cytokines--genetics<br/>Deoxycytidine--analogs & derivatives<br/>Disease-Free Survival<br/>Female<br/>Fluorouracil--analogs & derivatives<br/>Genetic Variation<br/>Genotype<br/>Humans<br/>Leucovorin--therapeutic use<br/>Male<br/>Middle Aged<br/>Neovascularization, Pathologic--drug therapy<br/>Organoplatinum Compounds--administration & dosage<br/>Oxaliplatin<br/>Oxaloacetates<br/>Pharmacogenetics<br/>Polymorphism, Restriction Fragment Length<br/>Polymorphism, Single Nucleotide<br/>Vascular Endothelial Growth Factor A--genetics